DEF: GoodRx Holdings Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals

GoodRx Holdings will hold its annual stockholders meeting virtually on June 3, 2025, to vote on director elections, auditor ratification, and executive compensation.

Summary

• GoodRx Holdings, Inc. will hold its 2025 Annual Meeting of Stockholders on June 3, 2025, at 12:00 p.m. Pacific Time, as a virtual meeting.
• Stockholders of record as of April 9, 2025, are entitled to vote.
• The meeting will address the election of Christopher Adams, Trevor Bezdek, and Scott Wagner as Class II Directors, ratification of PricewaterhouseCoopers LLP as the independent accounting firm, and an advisory vote on executive compensation.
• The Board recommends voting FOR all proposals.
• The proxy statement and 2024 Annual Report are available online, and voting can be done via internet, phone, or mail.
• At the close of business on the Record Date, there were 102,468,711 shares of Class A common stock and 256,869,320 shares of Class B common stock issued and outstanding and entitled to vote at the Annual Meeting, representing approximately 3.8% and 96.2% of the voting power of our Common Stock, respectively.

Sentiment

Score: 7

Explanation: The document is neutral in tone, presenting standard corporate governance matters. The positive financial performance metrics contribute to a slightly positive outlook.

Positives

• The company is providing a virtual meeting format to allow for increased stockholder attendance and participation.
• The Board is recommending a vote FOR all proposals, indicating confidence in the company's direction.
• The company has stock ownership guidelines in place to align the interests of executive officers and directors with those of stockholders.
• The company has a clawback policy in place that provides that we will recover any incentive-based compensation (whether cash or equity) received during the period of time specified in the policy by any current or former executive officer (as defined in Rule 10D-1(d) of the Exchange Act) which was predicated upon achieving certain financial results that were subsequently the subject of an accounting restatement.
• Revenue grew 6% year-over-year, net income in 2024 was $16.4 million compared to net loss in 2023 of $8.9 million, and Adjusted EBITDA increased 20% compared to 2023.

Negatives

• As a controlled company, GoodRx is exempt from certain Nasdaq corporate governance requirements, which may reduce protections for stockholders.
• The Board's division into three classes with staggered terms may delay or prevent a change of management or control of the company.
• The Sponsor Stockholders, acting in conjunction, will control the election of our directors.

Risks

• The proxy statement notes that the Sponsor Stockholders, acting in conjunction, will control the election of directors, which could lead to decisions that benefit those stockholders over others.
• The company's reliance on certain exemptions as a controlled company could result in less independent oversight.
• The division of the Board into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control of the Company.

Future Outlook

The document does not contain specific forward-looking statements beyond the scheduling of the annual meeting and the proposals to be voted on.

Industry Context

The document does not provide specific details on how this announcement relates to broader industry trends or competitors, but the discussion of strategic initiatives suggests a focus on maintaining competitiveness in the evolving healthcare technology landscape.

Management Changes

Stakeholder Impact

• Shareholders are asked to vote on key decisions affecting the company's governance and executive compensation.
• Employees are indirectly affected by the decisions on executive compensation and the overall direction of the company.
• Customers may be impacted by the company's strategic direction and financial performance.

Next Steps

• Stockholders are urged to vote on the proposals.
• The company will announce preliminary voting results at the Annual Meeting and report the final results in a Current Report on Form 8-K.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Board of Directors, Stockholders, Director Election, Executive Compensation, PricewaterhouseCoopers, Corporate Governance, GoodRx